IRIS
LOSURDO, GIUSEPPE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.663
AS - Asia 2.935
EU - Europa 2.430
SA - Sud America 710
Continente sconosciuto - Info sul continente non disponibili 601
AF - Africa 114
OC - Oceania 7
Totale 15.460
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.495
SG - Singapore 1.163
IT - Italia 817
CN - Cina 582
BR - Brasile 562
RU - Federazione Russa 375
HK - Hong Kong 372
SE - Svezia 333
DE - Germania 246
VN - Vietnam 243
FR - Francia 150
GB - Regno Unito 142
BD - Bangladesh 108
FI - Finlandia 102
IN - India 96
CA - Canada 84
ID - Indonesia 58
IQ - Iraq 55
BE - Belgio 51
AR - Argentina 47
TR - Turchia 43
MX - Messico 42
NL - Olanda 37
PL - Polonia 34
CO - Colombia 33
ZA - Sudafrica 32
PK - Pakistan 31
ES - Italia 30
UA - Ucraina 26
EC - Ecuador 24
UZ - Uzbekistan 22
JP - Giappone 21
SA - Arabia Saudita 21
IE - Irlanda 14
MA - Marocco 14
EG - Egitto 13
PH - Filippine 13
VE - Venezuela 13
AT - Austria 11
CI - Costa d'Avorio 11
DZ - Algeria 11
MY - Malesia 11
PE - Perù 10
AE - Emirati Arabi Uniti 9
AZ - Azerbaigian 9
JO - Giordania 9
TN - Tunisia 9
AL - Albania 8
CL - Cile 8
GR - Grecia 7
JM - Giamaica 7
KE - Kenya 7
KZ - Kazakistan 7
RO - Romania 7
AU - Australia 6
CH - Svizzera 6
IL - Israele 6
KR - Corea 6
LB - Libano 6
NP - Nepal 6
TH - Thailandia 6
BO - Bolivia 5
EU - Europa 5
GT - Guatemala 5
LT - Lituania 5
PS - Palestinian Territory 5
PY - Paraguay 5
QA - Qatar 5
BG - Bulgaria 4
HN - Honduras 4
MK - Macedonia 4
NI - Nicaragua 4
PA - Panama 4
TT - Trinidad e Tobago 4
BB - Barbados 3
CZ - Repubblica Ceca 3
DO - Repubblica Dominicana 3
ET - Etiopia 3
GA - Gabon 3
GE - Georgia 3
KG - Kirghizistan 3
LV - Lettonia 3
MD - Moldavia 3
OM - Oman 3
TW - Taiwan 3
BA - Bosnia-Erzegovina 2
BW - Botswana 2
CR - Costa Rica 2
EE - Estonia 2
IR - Iran 2
KW - Kuwait 2
PR - Porto Rico 2
SN - Senegal 2
SY - Repubblica araba siriana 2
UY - Uruguay 2
ZW - Zimbabwe 2
AG - Antigua e Barbuda 1
AM - Armenia 1
BH - Bahrain 1
BJ - Benin 1
Totale 14.845
Salva come PNG Salva come JPEG
Città #
Ashburn 880
Fairfield 869
Woodbridge 626
Singapore 616
Chandler 449
San Jose 409
Houston 380
Hong Kong 369
Seattle 342
Wilmington 299
Milan 297
Cambridge 293
Ann Arbor 286
Nyköping 278
Council Bluffs 218
Beijing 214
New York 188
Dallas 162
Los Angeles 111
Rome 91
Jacksonville 89
Lawrence 89
Roxbury 85
Lauterbourg 78
Ho Chi Minh City 74
Santa Clara 70
Nanjing 67
Boardman 63
Munich 60
Des Moines 55
Bari 54
Helsinki 54
Inglewood 54
Brussels 51
Columbus 51
São Paulo 49
Brooklyn 45
Hanoi 45
Atlanta 42
Princeton 39
Buffalo 37
Jakarta 35
Frankfurt am Main 32
Orem 32
San Diego 32
Dearborn 31
Chicago 30
Denver 28
Warsaw 28
Montreal 27
Turin 27
San Francisco 26
Phoenix 25
Falkenstein 23
Nuremberg 21
Dhaka 20
London 20
Bologna 19
Dong Ket 19
Figino 19
Rio de Janeiro 19
Tokyo 19
Baghdad 18
Hebei 18
Mexico City 18
Paris 18
Stockholm 18
Tashkent 18
Belo Horizonte 17
Johannesburg 17
The Dalles 17
Haiphong 16
Nanchang 16
Toronto 15
Chennai 14
Istanbul 14
Jiaxing 14
Medellín 14
Tianjin 14
Brasília 13
Dublin 13
Shenyang 13
Palermo 12
Pune 12
Abidjan 11
Boston 11
Curitiba 11
Da Nang 11
Lahore 11
Cairo 10
Philadelphia 10
Amsterdam 9
Naples 9
Poplar 9
Redwood City 9
Amman 8
Ankara 8
Baku 8
Buenos Aires 8
Guangzhou 8
Totale 9.650
Salva come PNG Salva come JPEG
Nome #
Effect of Long-Term Proton Pump Inhibitor Use on Blood Vitamins and Minerals: A Primary Care Setting Study 678
Extra-intestinal manifestations of non-celiac gluten sensitivity: An expanding paradigm 277
Concomitant and Bismuth Quadruple Therapy for Helicobacter pylori Eradication in Southern Italy: Preliminary Data from a Randomized Clinical Trial 241
Small intestinal bacterial overgrowth and celiac disease: A systematic review with pooled-data analysis 211
Differences in dietary habits between patients with inflammatory bowel disease in clinical remission and a healthy population 211
Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Disease: Prevalence and Risk Factors 210
Gastrointestinal bleeding from vascular malformations: Is octreotide effective to rescue difficult-to-treat patients? 201
Chemoprevention of inflammation-related colorectal cancer by silymarin-, acetyl-11-keto-beta-boswellic acid-, curcumin- and maltodextrin-enriched dietetic formulation in animal model 198
Systematic review with meta-analysis: post-operative complications and mortality risk in liver transplant candidates with obesity. 197
Evolution of nonspecific duodenal lymphocytosis over 2 years of follow-up 192
Systematic review: Renin-angiotensin system inhibitors in chemoprevention of hepatocellular carcinoma 192
May the assessment of baseline mucosal molecular pattern predict the development of gluten related disorders among microscopic enteritis? 191
Curcumin and colorectal cancer: From basic to clinical evidences 175
Tailored therapy guided by multichannel intraluminal impedance pH monitoring for refractory non-erosive reflux disease 169
The helper lymphocyte and mast cell immunohistochemical pattern in nonceliac gluten sensitivity 167
Stool Investigations for Colorectal Cancer Screening: From Occult Blood Test to DNA Analysis 157
Breath tests for the non-invasive diagnosis of small intestinal bacterial overgrowth: A systematic review with meta-analysis 156
The influence of small intestinal bacterial overgrowth in digestive and extra-intestinal disorders 152
Chronic viral hepatitis in a cohort of inflammatory bowel disease patients from southern Italy: A case-control study 149
Fibrogenesis and fibrosis in inflammatory bowel diseases: Good and bad side of same coin? 148
What Is the Optimal Follow-up Time to Ascertain the Safety of Proton Pump Inhibitors? 147
Non steroidal anti-inflammatory drug induced damage on lower gastro-intestinal tract: is there an involvement of microbiota? 145
Inter-observer agreement of a new endoscopic score for ulcerative colitis activity: Preliminary experience 145
Helicobacter pylori primary and secondary genotypic resistance to clarithromycin and levofloxacin detection in stools: A 4-year scenario in Southern Italy 143
Intestinal microbiota: The explosive mixture at the origin of inflammatory bowel disease? 140
Predictivity of Autoimmune Stigmata for Gluten Sensitivity in Subjects with Microscopic Enteritis: A Retrospective Study 136
Comparison of Transient Elastography and Point Shear Wave Elastography for Analysis of Liver Stiffness: A Prospective Study 134
Prevalence and associated factors of obesity in inflammatory bowel disease: A case-control study 130
Lymphocytic duodenitis or microscopic enteritis and gluten-related conditions: What needs to be explored? 128
An uncommon etiology of pancreatitis after endoscopic ultrasound-guided fine needle aspiration 125
Acute pancreatitis in elderly patients: A retrospective evaluation at hospital admission 125
Serrated Colorectal Lesions: An Up-to-Date Review from Histological Pattern to Molecular Pathogenesis 121
Systematic review with meta-analysis: de novo non-alcoholic fatty liver disease in liver-transplanted patients 120
Optimizing proton pump inhibitors in Helicobacter pylori treatment: Old and new tricks to improve effectiveness 120
Seronegative celiac disease: where is the specific setting? 116
The puzzle of coccoid forms of helicobacter pylori: Beyond basic science 116
Histamine and histaminergic receptors in colorectal cancer: From basic science to evidence-based medicine 115
Silymarin, boswellic acid and curcumin enriched dietetic formulation reduces the growth of inherited intestinal polyps in an animal model 114
Escherichia coli Nissle 1917 in ulcerative colitis treatment: Systematic review and meta-analysis 113
Checkpoint Inhibitor-Induced Colitis: An Update 112
Assessment of body composition: Intrinsic methodological limitations and statistical pitfalls 111
Human leukocyte antigen (Hla) haplotype does not influence the inflammatory pattern of duodenal lymphocytosis linked to irritable bowel syndrome 110
Low Molecular Weight Heparin in Portal Vein Thrombosis of Cirrhotic Patients: Only Therapeutic Purposes? 107
Endoscopic stenting for colorectal cancer obstruction as a bridge-to-surgery strategy 106
Role of concomitant therapy for Helicobacter pylori eradication: A technical note 102
Might helicobacter pylori play a role in allergic or cross-reaction related disorders? 102
null 101
The spectrum of small intestinal lesions in patients with unexplained iron deficiency anemia detected by video capsule endoscopy 101
null 100
null 99
Liver involvement in inflammatory bowel disease: What should the clinician know? 97
A case of severe transaminase elevation following a single ustekinumab dose with remission after drug withdrawal 97
Trends of Liver Stiffness in Inflammatory Bowel Disease with Chronic Hepatitis C 97
Estrogen receptors in colorectal cancer: Facts, novelties and perspectives 96
null 94
Primary clarithromycin resistance to Helicobacter pylori: Is this the main reason for triple therapy failure? 92
Endothelial function and cardiovascular risk in patients with inflammatory bowel disease in remission phase 91
Molecular Pathways of Carcinogenesis in Familial Adenomatous Polyposis 89
Empiric “Three-in-One” Bismuth Quadruple Therapy for Second-Line Helicobacter pylori Eradication: An Intervention Study in Southern Italy 88
Noninvasive molecular analysis of Helicobacter pylori: is it time for tailored first-line therapy? 88
Biological markers for non-celiac gluten sensitivity: A question awaiting for a convincing answer 88
Validation of a new optical diagnosis training module to improve dysplasia characterization in inflammatory bowel disease: a multicenter international study 87
A prospective trial in Saudi Arabia comparing the 14-day standard triple therapy with the 10-day sequential therapy for treatment of Helicobacter pylori infection: A further confirmation of geographic Weight 87
Editorial: liver transplantation in patients with non-alcoholic fatty liver disease and obesity—authors’ reply 87
null 86
null 86
Letter: Portal vein obstruction - Which subset of patients could benefit the most? 86
null 85
Familial adenomatous polyposis small bowel surveillance: could indicators for video-capsule endoscopy be ascertained? 85
Epstein-Barr Virus-Related hyperacute hepatitis: May intravenous Ster-Oids be an effective approach? 84
Does infliximab short infusion have a beneficial impact on the quality of life in patients with inflammatory bowel diseases? A single centre prospective evaluation 83
null 82
Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg) 81
null 81
null 81
Mucosal molecular pattern of tissue transglutaminase and interferon gamma in suspected seronegative celiac disease at marsh 1 and 0 stages 81
Letter: dose-response analysis revealed closer relationship between obesity and perioperative outcomes in patients after liver transplantation—Authors’ reply 81
Hydradenitis suppurativa and inflammatory bowel disease: An unusual, but existing association 81
Familial intestinal polyposis and device assisted enteroscopy: where do we stand? 80
Rifabutin as salvage therapy for Helicobacter pylori eradication: Cornerstones and novelties 80
null 80
Fibres and Colorectal Cancer: Clinical and Molecular Evidence 79
null 79
null 79
Second-line Therapy for Helicobacter Pylori Eradication: State of the Art 77
Effect of metronidazole resistance on Helicobacter pylori eradication regimens 77
Effect of Visual Booklets to Improve Bowel Preparation in Colonoscopy: Systematic Review with Meta-Analysis 77
Helicobacter pylori Secondary Antibiotic Resistance after One or More Eradication Failure: A Genotypic Stool Analysis Study 77
Experience with Rifabutin-Containing Therapy in 500 Patients from the European Registry on Helicobacter pylori Management (Hp-EuReg) 76
Sequential therapy for helicobacter pylori in elderly patients: Effectiveness, safety and predictors of success 76
Primary biliary cholangitis triggered by DAAs-induced HCV clearance: a biological proof of concept 75
null 74
Intestinal microbiota: the explosive mixture for inflammatory bowel disease pathogenesis? 73
null 73
null 73
null 72
null 72
The State of the Art of Molecular Fecal Investigations for Helicobacter pylori (H. pylori) Antibiotic Resistances 72
null 71
null 71
Totale 11.960
Salva come PNG Salva come JPEG
Categoria #
all - tutte 60.266
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 60.266
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022594 0 0 14 17 45 70 20 32 52 62 115 167
2022/20231.115 148 187 85 74 90 169 21 134 152 5 32 18
2023/2024416 29 69 16 47 26 137 6 7 2 34 8 35
2024/20252.039 56 25 106 32 38 183 297 210 93 136 285 578
2025/20265.419 724 242 332 470 641 215 484 149 785 576 209 592
2026/20271.490 826 400 264 0 0 0 0 0 0 0 0 0
Totale 15.460